National Mammography Quality Assurance Advisory Committee; Notice of Meeting, 51823-51824 [E7-17795]
Download as PDF
<![CDATA[
51823
Federal Register / Vol. 72, No. 175 / Tuesday, September 11, 2007 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30 Day–07–0398x]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) publishes a list of
information collection requests under
review by the Office of Management and
Budget (OMB) in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
requests, call the CDC Reports Clearance
Officer at (404) 639–5960 or send an email to omb@cdc.gov. Send written
comments to CDC Desk Officer, Office of
Management and Budget, Washington,
DC or by fax to (202) 395–6974. Written
comments should be received within 30
days of this notice.
Proposed Project
Evaluation of an Intervention to
Increase Colorectal Cancer Screening in
Primary Care Clinics-New-National
Center for Chronic Disease Prevention
and Health Promotion (NCDDPHP),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
Colorectal cancer (CRC) is the third
most frequent form of cancer and the
second leading cause of cancer-related
average-risk patients aged 50–80 years,
clinicians, and clinic support staff
within the primary care clinics in two
managed care organizations (MCOs).
There are three tasks in this study. In
Task 1, 140 primary care clinicians will
complete a survey assessing
demographics, opinions about
preventive services, CRC screening
training and practices, satisfaction with
CRC screening, and CRC screening
beliefs, facilitators, and barriers. The
survey will be administered to primary
care clinicians post-intervention. In
Task 2, 140 clinic support staff will
complete a survey assessing
demographics, work-related
responsibilities, opinions about
preventive services, CRC training and
practices, satisfaction with CRC
screening, and CRC screening beliefs,
facilitators and barriers. The survey will
be administered to clinic support staff
post intervention. In Task 3, clinic
patients will complete a survey
assessing demographics, health status,
receipt of previous CRC screening and
other preventive services, knowledge
and opinions about CRC and CRC
screening, and social support. The
survey will be administered to 3307
patients pre-intervention and 3307
patients post-intervention.
There will be no cost to respondents
other than their time. The total
estimated annualized burden hours are
2352.
deaths among both men and women in
the United States. Research shows that
screening can reduce both the
occurrence of colorectal cancer and
colorectal cancer deaths. Screening is
beneficial for: (1) Detection and removal
of precancerous polyps, resulting in
patients recovering without progression
to a diagnosis of cancer, and (2) early
detection of CRC for more effective
treatment and improved survival.
Regular CRC screening is recommended
for people aged 50 years and older.
Many screening tests are widely
available and screening has been shown
to be effective in reducing CRC
mortality. Despite this demonstrated
effectiveness, CRC screening remains
low. Some reasons attributed to the low
screening rates include limited public
awareness of CRC and the benefits of
screening, failure of health care
providers to recommend screening to
patients, and inefficient surveillance
and support systems in many health
care settings.
The purpose of this study is to
evaluate and understand the effect of a
multi-component intervention on CRC
screening rates in primary care clinics.
The study will also examine the effects
of the intervention conditions on
behavioral outcomes (e.g., clinicianpatient discussions about CRC
screening) and on attitudes, beliefs,
opinions, and social influence
surrounding CRC screening among
patients. The target population includes
ESTIMATE OF ANNUALIZED BURDEN HOURS
Number of
respondents
Respondents
Clinicians ......................................................................................................................................
Clinic Support Staff ......................................................................................................................
Patients surveyed only at baseline ..............................................................................................
Patients surveyed at baseline and follow-up ...............................................................................
Patients surveyed only at follow-up .............................................................................................
Dated: September 5, 2007.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E7–17837 Filed 9–10–07; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
National Mammography Quality
Assurance Advisory Committee;
Notice of Meeting
sroberts on PROD1PC70 with NOTICES
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
VerDate Aug<31>2005
17:06 Sep 10, 2007
Jkt 211001
PO 00000
Frm 00052
Fmt 4703
Sfmt 4703
140
140
2335
972
2335
Number of
responses per
respondent
1
1
1
2
1
Average
burden per
response
(in hours)
30/60
25/60
20/60
20/60
20/60
(FDA). The meeting will be open to the
public.
Name of Committee: National
Mammography Quality Assurance
Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on November 5, 2007, from 9 a.m.
to 5 p.m.
Location: Crown Plaza Rockville,
Remington II and III in the Ballroom, 3
Research Ct., Rockville, MD.
E:\FR\FM\11SEN1.SGM
11SEN1
sroberts on PROD1PC70 with NOTICES
51824
Federal Register / Vol. 72, No. 175 / Tuesday, September 11, 2007 / Notices
Contact Person: Nancy Wynne, Center
for Devices and Radiological Health
(HFZ–240), Food and Drug
Administration, 1350 Piccard Dr.,
Rockville, MD 20850, 240–276–3284, or
FDA Advisory Committee Information
Line, 1–800–741–8138 or 301–443–0572
in the Washington, DC area), code
3014512397. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: The committee will discuss
issues related to possible regulation of
interventional mammography and
receive input from professional
organizations. The committee will also
receive updates on recently approved
alternative standards. FDA intends to
make background material available to
the public no later than 2 business days
before the meeting. If FDA is unable to
post the background material on its Web
site prior to the meeting, the background
material will be made publicly available
at the location of the advisory
committee meeting, and the background
material will be posted on FDA’s Web
site after the meeting. Background
material is available at https://
www.fda.gov/ohrms/dockets/ac/
acmenu.htm, click on the year 2007 and
scroll down to the appropriate advisory
committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before October 5, 2007.
Oral presentations from the public will
be scheduled between approximately
9:30 a.m. and 11:45 a.m. and between
approximately 1 p.m. and 2 p.m. Those
desiring to make formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before
September 27, 2007. Time allotted for
each presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
VerDate Aug<31>2005
17:06 Sep 10, 2007
Jkt 211001
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by September 28, 2007.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Shirley
Meeks, Conference Management Staff, at
240–276–8931, at least 7 days in
advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/oc/advisory/
default.htm for procedures on public
conduct during advisory committee
meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: September 5, 2007.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E7–17795 Filed 9–10–07; 8:45 am]
In addition, the Council will be holding a
public hearing at which migrant
farmworkers, community leaders, and
providers will have the opportunity to testify
before the Council regarding matters that
affect the health of migrant farmworkers. The
hearing is scheduled for Thursday, October
18 from 9 a.m. to 12 p.m., at the Royal Plaza.
The Council meeting is being held in
conjunction with the 20th Annual East Coast
Migrant Stream Forum sponsored by the
North Carolina Community Health Center
Association, which is being held in Lake
Buena Vista, Florida, October 18–20, 2007.
Agenda items are subject to change as
priorities indicate.
For Further Information Contact: Gladys
Cate, Office of Minority and Special
Populations, Bureau of Primary Health Care,
Health Resources and Services
Administration, 5600 Fishers Lane, Maryland
20857; telephone (301) 594–0367.
Dated: September 4, 2007.
Alexandra Huttinger,
Acting Director, Division of Policy Review
and Coordination.
[FR Doc. E7–17825 Filed 9–10–07; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
BILLING CODE 4160–01–S
[USCG–2007–28121]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Collection of Information Under
Review by Office of Management and
Budget: OMB Control Numbers: 1625–
0025 and 1625–0058
Health Resources and Services
Administration
National Advisory Council on Migrant
Health; Notice of Meeting
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), notice is hereby given
of the following meeting:
Name: National Advisory Council on
Migrant Health.
Dates and Times: October 17, 2007, 8:30
a.m. to 5 p.m.; October 18, 2007, 8:30 a.m.
to 5 p.m.
Place: Royal Plaza, 1905 Hotel Plaza
Boulevard, Lake Buena Vista, Florida 32830,
Telephone: (407) 828–2828, Fax: (407) 827–
6338.
Status: The meeting will be open to the
public.
Purpose: The purpose of the meeting is to
discuss services and issues related to the
health of migrant and seasonal farmworkers
and their families and to formulate
recommendations for the Secretary of Health
and Human Services.
Agenda: The agenda includes an overview
of the Council’s general business activities.
The Council will also hear presentations
from experts on farmworker issues, including
the status of farmworker health at the local
and national levels.
PO 00000
Frm 00053
Fmt 4703
Sfmt 4703
Coast Guard, DHS.
Request for comments.
AGENCY:
ACTION:
SUMMARY: In compliance with the
Paperwork Reduction Act of 1995, this
request for comments announces that
the Coast Guard is forwarding two
Information Collection Requests (ICRs),
abstracted below, to the Office of
Information and Regulatory Affairs
(OIRA) of the Office of Management and
Budget (OMB) requesting an extension
of their approval for the following two
collections of information: (1) 1625–
0025, Carriage of Bulk Solids Requiring
Special Handling—46 CFR part 148; and
(2) 1625–0058, Application for Permit to
Transport Municipal and Commercial
Waste. Our ICRs describe the
information we seek to collect from the
public. Review and comments by OIRA
ensure we only impose paperwork
burdens commensurate with our
performance of duties.
DATES: Please submit comments on or
before October 11, 2007.
ADDRESSES: To make sure your
comments and related material do not
enter the docket [USCG–2007–28121] or
E:\FR\FM\11SEN1.SGM
11SEN1
]]>Agencies
[Federal Register Volume 72, Number 175 (Tuesday, September 11, 2007)]
[Notices]
[Pages 51823-51824]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-17795]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
National Mammography Quality Assurance Advisory Committee; Notice
of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: National Mammography Quality Assurance Advisory
Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on November 5, 2007, from 9
a.m. to 5 p.m.
Location: Crown Plaza Rockville, Remington II and III in the
Ballroom, 3 Research Ct., Rockville, MD.
[[Page 51824]]
Contact Person: Nancy Wynne, Center for Devices and Radiological
Health (HFZ-240), Food and Drug Administration, 1350 Piccard Dr.,
Rockville, MD 20850, 240-276-3284, or FDA Advisory Committee
Information Line, 1-800-741-8138 or 301-443-0572 in the Washington, DC
area), code 3014512397. Please call the Information Line for up-to-date
information on this meeting. A notice in the Federal Register about
last minute modifications that impact a previously announced advisory
committee meeting cannot always be published quickly enough to provide
timely notice. Therefore, you should always check the agency's Web site
and call the appropriate advisory committee hot line/phone line to
learn about possible modifications before coming to the meeting.
Agenda: The committee will discuss issues related to possible
regulation of interventional mammography and receive input from
professional organizations. The committee will also receive updates on
recently approved alternative standards. FDA intends to make background
material available to the public no later than 2 business days before
the meeting. If FDA is unable to post the background material on its
Web site prior to the meeting, the background material will be made
publicly available at the location of the advisory committee meeting,
and the background material will be posted on FDA's Web site after the
meeting. Background material is available at https://www.fda.gov/ohrms/
dockets/ac/acmenu.htm, click on the year 2007 and scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
October 5, 2007. Oral presentations from the public will be scheduled
between approximately 9:30 a.m. and 11:45 a.m. and between
approximately 1 p.m. and 2 p.m. Those desiring to make formal oral
presentations should notify the contact person and submit a brief
statement of the general nature of the evidence or arguments they wish
to present, the names and addresses of proposed participants, and an
indication of the approximate time requested to make their presentation
on or before September 27, 2007. Time allotted for each presentation
may be limited. If the number of registrants requesting to speak is
greater than can be reasonably accommodated during the scheduled open
public hearing session, FDA may conduct a lottery to determine the
speakers for the scheduled open public hearing session. The contact
person will notify interested persons regarding their request to speak
by September 28, 2007.
Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Shirley Meeks,
Conference Management Staff, at 240-276-8931, at least 7 days in
advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at https://www.fda.gov/oc/advisory/
default.htm for procedures on public conduct during advisory committee
meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: September 5, 2007.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E7-17795 Filed 9-10-07; 8:45 am]
BILLING CODE 4160-01-S
